Transforming growth factor-β in breast cancer: A working hypothesis

Breast Cancer Research and Treatment

Volumn 45, Issue 1, 1997, Pages 81-95

  Reiss, Michael ^a   Barcellos Hoff, Mary Helen ^b  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b LAWRENCE BERKELEY NATIONAL LABORATORY   (United States)

Author keywords

Activation; Breast cancer; Chemoprevention; Receptors; Resistance; Tamoxifen; TGF

Indexed keywords

TAMOXIFEN; TRANSFORMING GROWTH FACTOR BETA;

ARTICLE; BREAST CANCER; BREAST EPITHELIUM; CANCER INHIBITION; CANCER INVASION; EXTRACELLULAR MATRIX; HUMAN; METASTASIS; PRIORITY JOURNAL;

NON-PROGRAMMATIC;

BREAST NEOPLASMS; CARCINOMA; CELL DIVISION; CELL LINE; FEMALE; HUMANS; RECEPTORS, TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA;

EID: 0030793645     PISSN: 01676806     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1005865812918     Document Type: Article

References (118)

1. Cordon-Cardo C: Mutations of cell cycle regulators. Biological and clinical implications for human neoplasia. Am J Pathol 147: 545-560, 1995
2. Hosobuchi M, Stampfer MR: Effects of transforming growth factor β on growth of human mammary epithelial cells in culture. In Vitro Cell Develop Biol 25: 705-713, 1989
3. Valverius EM, Walker-Jones D, Bates SE, Stampfer MR, Clark R, McCormick F, Dickson RB, Lippman ME: Production of and responsiveness to transforming growth factor-β in normal and oncogene-transformed human mammary epithelial cells. Cancer Res 49: 6269-6274, 1989
4. Robinson SD, Silberstein GB, Roberts AB, Flanders KC, Daniel CW: Regulated expression and growth inhibitory effects of transforming growth factor-beta isoforms in mouse mammary gland development. Development 113: 867-878, 1991
5. Silberstein GB, Flanders KC, Roberts AB, Daniel CW: Regulation of mammary morphogenesis: evidence for extracellular matrix-mediated inhibition of ductal budding by transforming growth factor-beta 1. Dev Biol 152: 354-362, 1992
6. Pierce DFJ, Johnson MD, Matsui Y, Robinson SD, Gold LI, Purchio AF, Daniel CW, Hogan BLM, Moses H: Inhibition of mammary duct development but not alveolar outgrowth during pregnancy in transgenic mouse expressing active TGFβ1. Genes & Dev 7: 2308-2317, 1993
7. Jhappan C, Geiser AG, Kordon EC, Bagheri D, Hennighausen AB, Roberts AB, Smith GH, Merlino G: Targeting expression of a transforming growth factor β1 transgene to the pregnant mammary gland inhibits alveolar development and lactation. EMBO J 12: 1835-1845, 1993
8. Strange R, Li F, Saurer S, Burkhardt A, Friis RR: Apoptotic cell death and tissue remodelling during mouse mammary gland involution. Development 115: 49-58, 1992
9. Wakefield LM, Letterio JJ, Geiser AG, Flanders KC, O'Shaughnessy J, Roberts AB, Sporn MB: Transforming growth factor-beta's in mammary tumorigenesis: promoters or antipromoters? Prog Clin Biol Res 391: 133-148, 1995
10. Fynan TM, Reiss M: Resistance to inhibition of cell growth by transforming growth factor-β and its role in oncogenesis. Crit Rev Oncogenesis 4: 493-540, 1993
11. Thompson NL, Flanders KC, Smith JM, Ellingsworth LR, Roberts AB, Sporn MB: Expression of transforming growth factor β1 in specific cells and tissues of adult and neonatal mice. J Cell Biol 108: 661-669, 1988
12. Li L, Hu J-S, Olson EN: Different members of the jun proto-oncogene family exhibit distinct patterns of expression in response to type β transforming growth factor. J Biol Chem 265: 1556-1562, 1990
13. Stampfer MR, Yaswen P, Alhadeff M, Hosoda J: TGF beta induction of extracellular matrix associated proteins in normal and transformed human mammary epithelial cells in culture is independent of growth effects. J Cell Physiol 155: 210-221, 1993
14. Arteaga CL, Tandon AK, Von Hoff DD, Osborne CK: Transforming growth factor-β: potential autocrine growth inhibitor of ostrogen receptor-negative human breast cancer cells. Cancer Res 48: 3898-3904, 1988
15. Kalkhoven E, Kwakkenbos-Isbrücker L, Mummery CL, De Laat SW, van den Eijnden-van Raaij AJM, van der Saag PT, van der Burg B: The role of TGFβ production in growth inhibition of breast-tumor cells by progestins. Int J Cancer 61: 80-86, 1995
16. Walker RA, Dearing SJ: Transforming growth factor beta 1 in ductal carcinoma in situ and invasive carcinomas of the breast. Eur J Cancer 28: 641-644, 1992
17. McCune BK, Mullin BR, Flanders KC, Jaffurs WJ, Mullen LT, Sporn MB: Localization of transforming growth factor-beta isotypes in lesions of the human breast [see comments]. Hum Pathol 23: 13-20, 1992
18. Dalal BI, Keown PA, Greenberg AH: Immunocytochemical localisation of secreted transforming growth factor-beta 1 to the advancing edges of primary tumors and to lymph node metastases of human mammary carcinoma. Am J Pathol 143: 381-389, 1993
19. Gorsch SM, Memoli VA, Stukel TA, Gold LI, Arrick BA: Immunohistochemical staining for transforming growth factor β1 associates with disease progression in human breast cancer. Cancer Res 52: 6949-6952, 1992
20. Welch DR, Fabra A, Nakajima M: Transforming growth factor β stimulates mammary adenocarcinoma cell invasion and metastatic potential. Proc Natl Acad Sci USA 87: 7678-7682, 1990
21. Arrick BA, Lopez AR, Elfman F, Ebner R, Damsky CH, Derynck R: Altered metabolic and adhesive properties and increased tumorigenesis associated with increased expression of transforming growth factor beta 1. J Cell Biol 118: 715-726, 1992
22. Arteaga CL, Hurd SD, Winnier AR, Johnson MD, Fendly BM, Forbes JT: Anti-transforming growth factor (TGF)-beta antibodies inhibit breast cancer cell tumorigenicity and increase mouse spleen natural killer cell activity. Implications for a possible role of tumor cell/host TGF-beta interactions in human breast cancer progression. J Clin Invest 92: 2569-2576, 1993
23. Arteaga CL, Carty-Dugger T, Moses HL, Hurd SD, Pietenpol JA: Transforming growth factor beta 1 can induce estrogen-independent tumorigenicity of human breast cancer cells in athymic mice. Cell Growth Differ 4: 193-201, 1993
24. Levin NA, Brzoska P, Gupta N, Minna JD, Gray JW, Christman MF: Identification of frequent novel genetic alterations in small cell lung carcinoma. Cancer Res 54: 5086-5091, 1994
25. Miyazono K, Hellman U, Wernstedt C, Heldin C-H: Latent high molecular weight complex of transforming growth factor-β from human platelets: a high molecular weight complex containing precursor sequences. J Biol Chem 263: 6407-6415, 1988
26. Massagué J: Receptors for the TGFβ family. Cell 69: 1067-1070, 1992
27. Miyazono K, Heldin C-H: Latent forms of TGFβ: molecular structure and mechanisms of activation. In: Bock GR, Marsh J (eds) Clinical Applications of TGFβ. Wiley, Chichester, 1991, pp 81-92
28. Border WA, Noble NA: Transforming growth factor β in tissue fibrosis. N Engl J Med 331: 1286-1292, 1994
29. Flaumenhaft R, Rifkin DB: The extracellular regulation of growth factor action. Mol Cell Biol 3: 1057-1065, 1992
30. Foekens JA, Schmitt M, van Putten WL, Peters HA, Bontenbal M, Janicke F, Klijn JG: Prognostic value of urokinase-type plasminogen activator in 671 primary breast cancer patients. Cancer Res 52: 6101-6105, 1992
31. Janicke F, Schmitt M, Pache L, Ulm K, Harbeck N, Hofler H, Graeff H: Urokinase (uPA) and its inhibitor PAI-1 are strong and independent prognostic factors in node-negativo breast cancer. Breast Cancer Res Treat 24: 195-208, 1993
32. Grondahl-Hansen J, Christensen IJ, Rosenquist C, Brunner N, Mouridsen HT, Dano K, Blichert-Toft M: High levels of urokinase-type plasminogen activator and its inhibitor PA 1-1 in cytosolic extracts of breast carcinomas are associated with poor prognosis. Cancer Res 53: 2513-2521, 1993
33. Odckon LE, Blasi F, Rifkin DB: Requirement for receptor-bound urokinase in plasmin-dependent cellular conversion of latent TGF-beta to TGF-beta. J Cell Physiol 158: 398-407, 1994
34. Nielsen BS, Sehested M, Timshel S, Pyke C, Dano K: Messenger RNA for urokinase plasminogen activator is expressed in myofibroblasts adjacent to cancer cells in human breast cancer. Lab Invest 74: 168-177, 1996
35. Barcellos-Hoff MH: Radiation-induced transforming growth factor β and subsequent extracellular matrix reorganization in murine mammary gland. Cancer Res 53: 3880-3886, 1993
36. Mackie EJ, Halfter W, Liverani D: Induction of tenascin in healing wounds. J Cell Biol 107: 2757-2767, 1988
37. Laurent TC, Fraser RE: Hyaluronan. FASEB J 6: 2397-2404, 1992
38. Chiquet-Ehrismann R, Mackie EJ, Pearson CA, Sakakura T: Tenascin: an extracellular matrix protein involved in tissue interactions during fetal development and oncogenesis. Cell 47: 131-139, 1986
39. Mackie EJ, Chiquet-Ehrismann R, Pearson CA, Inaguma Y, Taya K, Kawarada Y, Sakakura T: Tenascin is a stromal marker for epithelial malignancy in the mammary gland. Proc Natl Acad Sci USA 84: 4621-4625, 1987
40. Howeedy AA, Virtanen I, Laitinen L, Gould NS, Koukoulis GK, Gould VE: Differential distribution of tenascin in the normal, hyperplastic, and neoplastic breast. Lab Invest 63: 798-806, 1990
41. Barcellos-Hoff MHR, Derynck R, Tsang L-S, Weatherbee JA: Transforming growth factor-β activation in irradiated murine mammary gland. J Clin Invest 93: 892-899, 1994
42. Fowlis DJ, Flanders KC, Duffie E, Balmain A, Akhurst RJ: Discordant localisation of TGFβ RNA and protein during chemical carcinogenesis in mouse skin. Cell Growth Differ 3: 81-91, 1992
43. Esheriek JS, DiCunto F, Flanders KC, Missero C, Dotto OP: Transforming growth factorβ1 induction is associated with transforming growth factorβ2 and β3 down-modulation in 12-O-tetradecanoylphorbol-13-acetate-induced skin hyperplasia. Cancer Res 53: 5507-5512, 1993
44. Barcellos-Hoff MH, Ehrhart EJ, Kalia M, Jirtle R, Flanders K, Tsang ML-S: Immunohistochemical detection of active TGFβ in situ using engineered tissue. Am J Pathol 147: 1228-1237, 1995
45. Jirtle RL, Hankinc GR, Reisenbichler H, Boyer IJ: Regulation of mannose-6-phosphate/insulin-like growth factor-II receptors and transforming growth factor beta during liver tumor promotion with phenobarbital. Carinogenesis 15: 1473-1478, 1994
46. Mansbach JM, Mills JJ, Boyer U, De Souza AT, Hankins OR, Jirtle RL: Phenobarbital selectively promotes initiated cells with reduced TGF beta receptor levels. Carcinogenesis 17: 171-174, 1996
47. Knabbe C, Lippman ME, Wakefield LM, Flanders KC, Kasid A, Derynck R, Dickson RB: Evidence that transforming growth factor-β is a hormonally regulated negative growth factor in human breast cancer cells. Cell 48: 417-428, 1987
48. Zugmaier G, Ennis BW, Deschauer B, Katz D, Knabbe C, Wilding G, Daly P, Lippman ME, Dickson RB: Transforming growth factor type β1 and β2 are equipotent growth inhibitors of human breast cancer cell lines. J Cell Physiol 141: 353-361, 1989
49. Herman ME, Katzenellenbogen BS: Alterations in transforming growth factor-alpha and -beta production and cell responsiveness during the progression of MCF-7 human breast cancer cells to estrogen-autonomous growth. Cancer Res 54: 5867-5874, 1994
50. Pierce DF Jr, Gorska AE, Chytil A, Meise KS, Page DL, Coffey RJ Jr, Moses HL: Mammary tumor suppression by transforming growth factor beta 1 transgene expression. Proc Natl Acad Sci USA 92: 4254-4258, 1995
51. Zugmaier G, Paik S, Wilding G, Knabbe C, Bano M, Lupu R, Deschauer B, Simpson S, Dickson RB, Lippman M: Transforming growth factor β1 induces cachexia and systemic fibrosis without an antitumor effect in nude mice. Cancer Res 51: 3590-3594, 1991
52. Lin HY, Wang X-F, Ng-Eaton E, Weinberg RA, Lodish HF: Expression cloning of the TGFβ type II receptor, a functional transmembrane serine/threonine kinase. Cell 68: 775-785, 1992
53. Franzé́n P, Ten Dijke P, Ichijo H, Yamashita H, Schutz P, Heldin C-H, Miyazono K: Cloning of a TGFβ type I receptor that forms a heterodimeric complex with the TGFβ type II receptor. Cell 75: 681-692, 1993
54. Lin HY, Moustakas A: TGF-beta receptors: structure and function. Cell Mol Biol 40: 337-349, 1994
55. ten Dijke P, Ichijo H, Franzen P, Schulz P, Saras J, Toyoshima H, Heldin C-H, Miyazono K: Activin receptor-like kinases: a novel subclass of cell-surface receptors with predicted serine/threonine kinase activity. Oncogene 8: 2879-2887, 1993
56. Attisano L, Wrana JL, Lopez-Casillas F, Massagué J: TGF beta receptors and actions. Biochim Biophys Acta 1222: 71-80, 1994
57. Chen R-H, Derynck R: Homomeric interactions between type II transforming growth factor-β receptors. J Biol Chem 269: 22868-22874, 1994
58. Wrana JL, Attisano L, Cárcamo J, Zentella A, Doody J, Laiho M, Wang X-F, Massagué J: TGFβ signals through a heteromeric protein kinase receptor complex. Cell 71: 1003-1014, 1992
59. Wrana JL, Attisano L, Wieser R, Ventura F, Massagué J: Mechanism of activation of the TGFβ receptor. Nature 370: 341-347, 1994
60. Wang T, Donahoe P, Zervos AS: Specific interaction of type I receptors of the TGFβ family with the immunophilin FKBP-12. Science 265: 674-676, 1994
61. Chen R-H, Miettinen PJ, Maruoka EM, Choy L, Derynck R: A WD-domain protein that is associated with and phosphoryluted by the type II TGF-β receptor. Nature 377: 548-552, 1995
62. Chomczynski P, Sacchi N: Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 162: 156-159, 1987
63. Van ZF, Winawer S, Fricdman E: Two different signal transduction pathways can be activated by transforming growth factor beta 1 in epithelial cells. J Biol Chem 269: 13231-13237, 1994
64. Yamaguchi K, Shirakabe K, Shibuya H, Irie K, Oishi I, Ueno N, Taniguchi T, Nishida E, Matsumoto K: Identification of a member of the MAPKKK family as a potential mediator of TGFβ signal transduction. Science 270: 2008-2011, 1995
65. Fischer JR, Darjes H, Lahm H, Schindel M, Drings P, Klammer PH: Constitutive secretion of bioactive transforming growth factor beta 1 by small lung cancer cell lines. Eur J Cancer 30A: 2125-2129, 1994
66. Nørgaard P, Damstrup L, Rygaard K, Spang-Thomsen M, Skovgaard Poulson H: Growth suppression by transforming growth factor beta 1 of human-cell lung cancer cell lines is associated with expression of the type II receptor. Br J Cancer 69: 802-808, 1994
67. INK4H is a potential effector of TGFβ-induced cell cycle arrest. Nature 371: 257-261, 1994
68. IN14B through an Sp1 consensus site. J Biol Chem 270: 26750-26753, 1995
69. Geng Y, Weinberg RA: Transforming growth factor β effects on expression of G1 cyclins and cyclin-dependent protein kinases. Proc Natl Acad Sci USA 90: 10315-10319, 1993
70. Ewen ME, Sluss HK, Whitehouse LL, Livingston DM: TGFβ inhibition of cdk4 synthesis is linked to cell cycle arrest. Cell 74: 1009-1020, 1993
71. Gerwein BI, Spillare H, Forrestier K, Lehman TA, Kispert J, Welsh JA, Pfeifer AMA, Lechner JF, Baker SJ, Vogelstein B, Harris CC: Mutant p53 can induce tumorigenic conversion of human bronchial epithelial cells and reduce their responsiveness to a negative growth factor, transforming growth factor β1. Proc Natl Acad Sci USA 89: 2759-2763, 1992
72. Reiss M, Vellucci VF, Zhou Z-L: Loss of sensitivity to the anti-proliferalive effect of transforming growth factor-β1 associated with the expression of mutant p53 tumor suppressor gene in murine keratinocytes. Cancer Res 53: 899-904, 1993
73. Okamoto A, Jiang W, Kim SJ, Spillare EA, Sloner G, Weinstein IB, Harris CC: Overexpression of human cyclin D1 reduces the transforming growth factor beta (TGF-beta) type II receptor and growth inhibition by TGF-beta 1 in an immortalized human esophageal epithelial cell line. Proc Natl Acad Sci USA 91: 11570-11580, 1994
74. Buckley MF, Sweeney KJ, Hamilton JA, Sini RL, Manning DL, Nicholson RI, deFazio A, Walts CK, Musgrove EA, Sutherland RL: Expression and amplification of cyclin genes in human breast cancer. Oncogcne 8: 2127-2133, 1993
75. Zukerberg LR, Yang WI, Gadd M, Thor AD, Koerner FC, Schmidt EV, Arnold A: Cyclin D1 (PRAD1) protein expression in breast cancer: approximately one-third of infiltrating mammary carcinomas show overexpression of the cyclin D1 oncogene. Mod Pathol 8: 560-567, 1995
76. Weinstat-Saslow D, Merino MJ, Manrow RE, Lawrence JA, Bluth RF, Wittenbel KD, Simpson JF, Page DL, Steeg PS: Overexpression of cyclin D mRNA distinguishes invasive and in situ breast carcinomas from non-malignant lesions. Nature Med 1: 1257-1260, 1995
77. Laiho M, Weis FMB, Boyd FT, Ignotz RA, Massagué J: Responsiveness to transforming growth factor-β (TGFβ) restored by complementation between cells defective in TGFβ receptors I and II. J Biol Chem 266: 9108-9112, 1991
78. Geiser AG, Burmester JK, Webbink R, Roberts AB, Sporn MB: Inhibition of growth by transforming growth factor-β following fusion of two nonresponsive human carcinoma cell lines. J Biol Chem 267: 2588-2593, 1992
79. Kalkhoven E, Roelen BAJ, de Winter JP, Mummery CL, van den Eijnden-van Raaij AJM, van der Saag PT, van der Burg B: Resistance to transforming growth factor β and activin due to reduced receptor expression in human breast tumor cell lines. Cell Growth Diff 6: 1151-1156, 1995
80. Sun L, Wu G, Willson JK, Zborowska E, Yang J, Rajkarunanayake I, Wang J, Gentry LE, Wang XF, Brattain MG: Expression of transforming growth factor beta type II receptor leads to reduced malignancy in human breast cancer MCF-7 cells. J Biol Chem 269: 26449-26455, 1994
81. Kim IY, Ahn H-J, Zelner DJ, Shaw JW, Sensibar JA, Kim J-H, Kalo M, Lee C: Genetic change in transforming growth factor-β (TGF-β) receptor type I gene correlates with insensitivity to TGFβ1 in human prostate cancer cells, Cancer Res 56: 44-48, 1996
82. Kadin ME, Cavaille-Coll MW, Gertz R, Massagué J, Cheifetz S, George D: Loss of receptors for transforming growth factor β in human T-cell malignancies. Proc Natl Acad Sci USA 91: 6002-6006, 1994
83. Capocasule RJ, Lamb RJ, Vonderheid EC, Fox FE, Rook AH, Nowell PC, Moore JS: Reduced surface expression of transforming growth factor β receptor type II in mitogenactivated T cells from Sćzary patients. Proc Natl Acad Sci USA 92: 5501-5505, 1995
84. Jakowlew SB, Mathias A, Chung P, Moody TW: Expression of transforming growth factor beta ligand and receptor messenger RNAs in lung cancer cell lines. Cell Growth Differ 6: 465-476, 1995
85. Damstrup L, Rygaard K, Spang-Thomsen M, Skovgaard Poulsen H: Expression of transforming growth factor beta (TGF beta) receptors and expression of TGF beta 1, TGF beta 2 and TGF beta 3 in human small cell lung cancer cell lines. Br J Cancer 67: 1015-1021, 1993
86. Friess H, Yamanaka Y, Büchler M, Beger HG, Kobrin MS, Baldwin RL, Kore M: Enhanced expression of the type II transforming growth factor β receptor in human pancreatic cancer cells without alteration of type II receptor expression. Cancer Res 53: 2704-2707, 1993
87. Garrigue-Antar L, Munoz-Antonia T, Antonia SJ, Gesmonde J, Vellucci VF, Reiss M: Missense mutations of the transforming growth factor beta type II receptor in human head and neck squamous carcinoma cells. Cancer Res 55: 3982-3987, 1995
88. Markowitz S, Wang J, Myeroff L, Parsons R, Sun L, Lutterbaugh J, Fan RS, Zborowska E, Kinzler KW, Vogelstein B, Brattain M, Willson JKV: Inactivation of the type II TGFβ receptor in colon cancer cells with microsatellite instability. Science 268: 1336-1338, 1995
89. Mycroff LL, Parsons R, Kim S-J, Hedrick L, Cho KR, Orth K, Mathis M, Kinzler KW, Lutterbaugh J, Park K, Bang Y-J, Lee HY, Park J-G, Lynch HT, Roberts AB, Vogelstein B, Markowitz SD: A transforming growth factor β type II gene mutation common in colon and gastric but rare in endometrial cancers with microsatellite instability. Cancer Res 55: 5545-5547, 1995
90. Parsons R, Myeroff LL, Liu B, Willson JKV, Markowitz SD, Kinzler KW, Vogelstein B: Microsatellite instability and mutations of the transforming growth factor β type II receptor gene in colorectal cancer. Cancer Res 55: 5548-5550, 1995
91. Pavelic K, Antonic M, Pavelic L, Pavelic J, Pavelic Z, Spaventi S: Human lung cancers growing on extracellular matrix: expression of oncogenes and growth factors. Anticancer Res 12: 2191-2196, 1992
92. Ke Y, Stoner GD, Demetrick DJ, Bennett WP: Mutation analysis of the transforming growth factor beta type II receptor in sporadic human cancers of the pancreas, liver and breast. Proc Am Assoc Cancer Res 37: 116, 1996
93. Roth JA, Mukhopadhyay T, Tainksky MA, Fang K, Casson AG, Schneider PM: Molecular approaches to prevention and therapy of aerodigestive tract cancers. Monogr Natl Cancer Inst 15-21, 1992
94. Ji H, Stout LE, Zhang Q, Zhang R, Leung HT, Leung BS: Absence of transforming growth factor-beta responsiveness in the tamoxifen growth-inhibited human breast cancer cell line CAMA-1. J Cell Biochem 54: 332-342, 1994
95. Kopp A, Jonat W, Schmahl M, Knabbe C: Transforming growth factor beta 2 (TGF-beta 2) levels in plasma of patients with metastatic breast cancer treated with tamoxifen. Cancer Res 55: 4512-4515, 1995
96. Knabbe C, Kopp A, Hilgers W, Lang D, Muller V, Zugmaier G, Jonat W: Regulation and role of TGF beta production in breast cancer. Ann NY Acad Sci 784: 263-276, 1996
97. Butta A, MacLennan K, Flanders KC, Sacks NPM, Smith I, McKinna A, Dowsett M, Wakefield LM, Sporn MB, Baum M, Colletta AA: Induction of transforming growth factor β1 in human breast cancer in vivo following tamoxifen treatment. Cancer Res 52: 4261-4264, 1992
98. Murray PA, Gomm J, Ricketts D, Powles T, Coombes RC: The effect of endocrine therapy on the levels of oestrogen and progesterone receptor and transforming growth factor-beta 1 in metastatic human breast cancer: an immunocytochemical study. Eur J Cancer 30A: 1218-1222, 1994
99. MacCallum J, Keen JC, Bartlett JM, Thompson AM, Dixon JM, Miller WR: Changes in expression of transforming growth factor beta mRNA isoform in patients undergoing tamoxifen therapy. Br J Cancer 74: 474-478, 1996
100. Benson JR, Wakefield LM, Baum M, Collelta AA: Synthesis and secretion of transforming growth factor beta isoforms by primary cultures of human breast tumour fibroblasts in vitro and their modulation by tamoxifen. Br J Cancer 74: 352-358, 1996
101. Group EBCTC: Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. Lancet 339: 1-15, 71-85, 1992
102. McGuire WL, Vollmer EP, Carbone PP: Estrogen Receptors in Human Breast Cancer. Raven Press, New York, 1975
103. Johnston SRD, Saccani-Jotti G, Smith IE, Salter J, Newby J, Coppen M, Ebbs SR, Dowsett M: Changes in estrogen receptor, progesterone receptor, and pS2 expression in tamoxifen-resistant human breast cancer. Cancer Res 55: 3331-3338, 1995
104. Karnik PS, Kulkarni S, Liu XP, Budd GT, Bukowski RM: Estrogen receptor mutations in tamoxifen-resistant breast cancer. Cancer Res 54: 349-353, 1994
105. Osborne CK, Fuqua SA: Mechanisms of tamoxifen resistance. Breast Cancer Res Treat 32: 49-55, 1994
106. Thompson AM, Kerr DJ, Steel CM: Transforming growth factor beta 1 is implicated in the failure of tamoxifen therapy in human breast cancer. Br J Cancer 63: 609-614, 1991
107. Foekens JA, Look MP, Peters HA, van Putten WL, Portengen H, Klijn JO: Urokinase-type plasminogen activator and its inhibitor PAI-1: predictors of poor response to tamoxifen therapy in recurrent breast cancer. J Natl Cancer Inst 87: 751-756, 1995
108. Herman JG, Latif F, Weng Y, Lerman MI, Zbar B, Liu S, Samid D, Duan DS, Gnarra JR, Linehan WM, Baylin SB: Silencing of the VHL tumor-suppressor gene by DNA methylation in renal carcinoma. Proc Natl Acad Sci USA 91: 9700-9704, 1994
109. Fisher B, Costantino J, Redmond C, Fisher E, Margolese R, Dimitrov N, Wolmark N, Wickerham DL, Deutsch M, Ore L, Mamounas E, Poller W, Kavanah M: Lumpectomy compared with lumpectomy and radiation therapy for the treatment of intraductal breast cancer. N Engl J Med 328: 1581-1586, 1993
110. Dickens TA, Colletta AA: The pharmacological manipulation of members of the transforming growth factor beta family in the chemoprevention of breast cancer. Bioassays 15: 71-74, 1993
111. Bush TL, Helzlsouer KJ: Tamoxifen for the primary prevention of breast cancer: a review and critique of the concept and trial. Epidemiol Rev 15: 233-243, 1993
112. Powles TJ, Jones AL, Ashley SE, O'Brien ME, Tidy VA, Treleavan J, Cosgrove D, Nash AG, Sacks N, Baum M, et al.: The Royal Marsden Hospital pilot lamoxifen chemoprevention trial. Breast Cancer Res Treat 31: 73-82, 1994
113. Kojima S, Rifkin DB: Mechanism of retinoid-induced activation of latent transforming growth factor-beta in bovine endothelial cells. J Cell Physiol 155: 323-332, 1993
114. Costa A, Formelli F, Chiesa F, Decensi A, De Palo G, Veronesi U: Prospects of chemoprevention of human cancers with the synthetic retinoid fenretinide. Cancer Res 54: 1994
115. Jirtle RL, Haag JD, Ariazi EA, Gould MN: Increased mannose-6-phosphate/insulin-like growth factor II receptor and transforming growth factor-β1 levels during monoterpene-induced regression of mammary tumors. Cancer Res 53: 3849-3852, 1993
116. Nørgaard P, Spang-Thomsen M, Poulsen HS: Expression and autoregulation of transforming growth factor β receptor mRNA in small-cell lung cancer cell lines. Br J Cancer 73: 1037-1043, 1996
117. Kashii T, Mizushima Y, Monno S, Nakagawa K, Kobayashi M: Gene analysis of K-, H-ras, p53, and retinoblastoma susceptibility genes in human lung cancer cell lines by the polymerase chain reaction/single-strand conformation polymorphism method. J Cancer Res Clin Oncol 120: 143-148, 1994
118. Niklinski J, Furman M: Clinical tumour markers in lung cancer. Eur J Cancer Prev 4: 129-138, 1995